Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core
Authors
Keywords
-
Journal
Pharmaceuticals
Volume 15, Issue 4, Pages 444
Publisher
MDPI AG
Online
2022-04-03
DOI
10.3390/ph15040444
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sulfonamide derivatives of cis-imidazolines as potent p53-MDM2/MDMX protein-protein interaction inhibitors
- (2021) Daniil R. Bazanov et al. MEDICINAL CHEMISTRY RESEARCH
- Synthesis of Covalent Conjugates of Dichloroacetic Acid with Polyfunctional Compounds
- (2021) D. R. Bazanov et al. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY
- Mutant p53 and Cellular Stress Pathways: A Criminal Alliance That Promotes Cancer Progression
- (2019) Gabriella D’Orazi et al. Cancers
- 2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation
- (2019) Daniil R. Bazanov et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
- (2019) Yao Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Development of selective small molecule MDM2 degraders based on nutlin
- (2019) Bo Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814
- (2019) Qing Sun et al. MOLECULAR CANCER RESEARCH
- p21 in Cancer Research
- (2019) Shamloo et al. Cancers
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
- (2017) Shaomeng Wang et al. Cold Spring Harbor Perspectives in Medicine
- Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage
- (2016) Ansar Karimian et al. DNA REPAIR
- Small-molecule MDM2-p53 inhibitors: recent advances
- (2015) Bian Zhang et al. Future Medicinal Chemistry
- Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
- (2014) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein–Protein Interaction Inhibitor
- (2013) David C. Fry et al. ACS Medicinal Chemistry Letters
- Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53–MDM2 binding inhibitors
- (2012) Chunqi Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A Practical Synthesis of a cis-4,5-Bis(4-chlorophenyl)imidazoline Intermediate for Nutlin Analogues
- (2012) Lianhe Shu et al. ORGANIC PROCESS RESEARCH & DEVELOPMENT
- Design, synthesis, and biological evaluation of imidazoline derivatives as p53–MDM2 binding inhibitors
- (2011) Chunqi Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
- (2011) Ruth Villalonga-Planells et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now